Takeda Pharmaceutical Revises FY2024 Financial Forecast

Takeda Pharmaceutical Company Limited has updated its financial forecasts for FY2024, ending March 31, 2025. The company anticipates consolidated revenue to reach JPY 4,590 billion, marking a 2.5% increase from the prior estimate. Operating profit is projected at JPY 344 billion, reflecting a significant 29.8% increase. This growth is primarily due to reduced generic competition for VYVANSE in the U.S. and favorable currency exchange rates.

Core revenue matches the revised overall revenue forecast, with core operating profit expected to rise by 9.5%, reaching JPY 1,150 billion. Net profit attributable to company owners is projected to be JPY 118 billion, a 73.5% increase, while basic EPS is revised to JPY 74.68, up by 73.5%.

The revisions are supported by positive business momentum and cost savings in R&D. However, some revenue adjustments arise from accounting processes related to foreign currency impacts on inventories. Management guidance now predicts slight increases in core figures, countering the earlier downside trends.